Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease.
Categories
- Anatomy
- Biochemistry
- BioEngineering
- BioInformatics
- Biology
- Biotechnology
- Cardiology
- Cell Medicine
- Cell Therapy
- Chemistry
- DNA
- Embryology
- Future Medicine
- Gene Medicine
- Gene Therapy
- Genetic Engineering
- Genetic Therapy
- Genetics
- Germ Line Engineering
- Human Genetics
- IVF Treatment
- Longevity Medicine
- Medical News
- Medical School
- Medical Technology
- Medicine
- Molecular Genetics
- Molecular Medicine
- Nano Medicine
- Nanotechnology
- Pet Stem Cell Therapy
- Stem Cell Therapy
Archives
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
Recommended Resources